Compare SXI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | EWTX |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 1994 | 2021 |
| Metric | SXI | EWTX |
|---|---|---|
| Price | $308.65 | $41.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $289.67 | $39.00 |
| AVG Volume (30 Days) | 174.4K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.98 | N/A |
| Revenue | ★ $604,535,000.00 | N/A |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $43.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $163.30 | $12.31 |
| 52 Week High | $363.89 | $48.40 |
| Indicator | SXI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 55.23 |
| Support Level | $297.07 | $29.03 |
| Resistance Level | $363.89 | $43.93 |
| Average True Range (ATR) | 10.37 | 2.56 |
| MACD | -2.18 | -0.32 |
| Stochastic Oscillator | 41.00 | 40.63 |
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.